| 发明名称 |
Derivatisation of Erythropoietin (EPO) |
| 摘要 |
The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. |
| 申请公布号 |
US2017119893(A1) |
申请公布日期 |
2017.05.04 |
| 申请号 |
US201715404896 |
申请日期 |
2017.01.12 |
| 申请人 |
Lipoxen Technologies Limited |
发明人 |
Jain Sanjay;Laing Peter;Gregoriadis Gregory;Rumpf Norbert Oskar |
| 分类号 |
A61P7/06;A61K38/18 |
主分类号 |
A61P7/06 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating an anemia in a patient comprising: administering a therapeutically effective amount of a composition comprising a polysialic acid (PSA) derivative of EPO and a pharmaceutically acceptable excipient to a patient in need thereof, wherein the EPO has at least 95% sequence identity to an amino acid sequence comprising SEQ ID NO:1, wherein the PSA is attached via an amine group located at to the amino-terminus of the EPO, and wherein the PSA has an average molecular weight in the range of about 5 kDa to about 50 kDa. |
| 地址 |
London GB |
